CTLA4 and juvenile dermatomyositis: The expression of Treg receptor GITR was not significantly different between healthy controls and patients (Figure 1D, control: 7.2% ±0.9 SEM, remission: 6.5% ±0.5 SEM, active: 7.2% ±0.5 SEM), while CTLA-4 expression was significantly lower in remitting JDM patients compared to controls, but not significantly different between active and remitting disease (Figure 1E, control: 61.7% ±5.3 SEM, remission: 44.0% ±3.5 SEM, active: 50.6% ±4.0 SEM).